Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFIRINOX vs mFOLFOX6 in High-risk Stage III Colon Cancer
NCT02967289Phase 3Completed
- Sponsor
- Unicancer
- Start
- Mar 2017
- Primary completion
- Jun 2025
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in colon cancer, sponsored by Unicancer. Started Mar 2017; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT02967289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02967289.